Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders

Psychiatry Research

Volumn 168, Issue 3, 2009, Pages 209-212

  Kim, Byungsu ^a   Kim, Chang Yoon ^a   Lee, Mi Jung ^a   Joo, Yeon Ho ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Bipolar disorder; Treatment response; Valproate; XBP1 116C G

Indexed keywords

VALPROIC ACID; X BOX BINDING PROTEIN 1;

ADULT; ALLELE; ARTICLE; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG RESPONSE; ENDOPLASMIC RETICULUM STRESS; FEMALE; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CHI-SQUARE DISTRIBUTION; DNA-BINDING PROTEINS; DROSOPHILA PROTEINS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; VALPROIC ACID;

EID: 67650490973     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.05.010     Document Type: Article

References (18)

1. Bown C.D., Wang J.F., Chen B., and Young L.T. Regulation of ER stress proteins by valproate: therapeutic implications. Bipolar Disorders 4 (2002) 145-151
2. Cichon S., Buervenich S., Kirov G., Akula N., Dimitrova A., Green E., Schumacher J., Klopp N., Becker T., Ohlraun S., Schulze T.G., Tullius M., Gross M.M., Jones L., Krastev S., Nikolov I., Hamshere M., Jones I., Czerski P.M., Leszczynska-Rodziewicz A., Kapelski P., Bogaert A.V., Illig T., Hauser J., Maier W., Berrettini W., Byerley W., Coryell W., Gershon E.S., Kelsoe J.R., McInnis M.G., Murphy D.L., Nurnberger J.I., Reich T., Scheftner W., O'Donovan M.C., Propping P., Owen M.J., Rietschel M., Nothen M.M., McMahon F.J., and Craddock N. Lack of support for a genetic association of the XBP1 promoter polymorphism with bipolar disorder in probands of European origin. Nature Genetics 36 (2004) 783-784 author reply 784-785
3. Dow G.S., Caridha D., Goldberg M., Wolf L., Koenig M.L., Yourick D.L., and Wang Z. Transcriptional profiling of mefloquine-induced disruption of calcium homeostasis in neurons in vitro. Genomics 86 (2005) 539-550
4. Evans W.E., and Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annual Reviews - Genomics and Human Genetics 2 (2001) 9-39
5. Even C., Friedman S., and Lanouar K. Bipolar disorder after mefloquine treatment. Journal of Psychiatry & Neuroscience 26 (2001) 252-253
6. Garnham J., Munro A., Slaney C., Macdougall M., Passmore M., Duffy A., O'Donovan C., Teehan A., and Alda M. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. Journal of Affective Disorders 104 (2007) 185-190
7. Grof P., Duffy A., Cavazzoni P., Grof E., Garnham J., MacDougall M., O'Donovan C., and Alda M. Is response to prophylactic lithium a familial trait?. Journal of Clinical Psychiatry 63 (2002) 942-947
8. Hiroi T., Wei H., Hough C., Leeds P., and Chuang D.M. Protracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: roles of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics Journal 5 (2005) 102-111
9. Hou S.J., Yen F.C., Cheng C.Y., Tsai S.J., and Hong C.J. X-box binding protein 1 (XBP1) C-116G polymorphisms in bipolar disorders and age of onset. Neuroscience Letters 367 (2004) 232-234
10. Inoue H., Tanizawa Y., Wasson J., Behn P., Kalidas K., Bernal-Mizrachi E., Mueckler M., Marshall H., Donis-Keller H., Crock P., Rogers D., Mikuni M., Kumashiro H., Higashi K., Sobue G., Oka Y., and Permutt M.A. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nature Genetics 20 (1998) 143-148
11. Kakiuchi C., Ishiwata M., Hayashi A., and Kato T. XBP1 induces WFS1 through an endoplasmic reticulum stress response element-like motif in SH-SY5Y cells. Journal of Neurochemistry 97 (2006) 545-555
12. Kakiuchi C., Iwamoto K., Ishiwata M., Bundo M., Kasahara T., Kusumi I., Tsujita T., Okazaki Y., Nanko S., Kunugi H., Sasaki T., and Kato T. Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nature Genetics 35 (2003) 171-175
13. Kakiuchi C., and Kato T. Lithium response and -116C/G polymorphism of XBP1 in Japanese patients with bipolar disorder. International Journal of Neuropsychopharmacology 8 (2005) 631-632
14. Masui T., Hashimoto R., Kusumi I., Suzuki K., Tanaka T., Nakagawa S., Kunugi H., and Koyama T. A possible association between the -116C/G single nucleotide polymorphism of the XBP1 gene and lithium prophylaxis in bipolar disorder. International Journal of Neuropsychopharmacology 9 (2006) 83-88
15. Shao L., Sun X., Xu L., Young L.T., and Wang J.F. Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sciences 78 (2006) 1317-1323
16. Swift M., and Swift R.G. Psychiatric disorders and mutations at the Wolfram syndrome locus. Biological Psychiatry 47 (2000) 787-793
17. Tor P.C., Lee H.Y., and Tan C.H. Mefloquine-induced mania in a 22-year-old Chinese man. Singapore Medical Journal 47 (2006) 549-550
18. Yoshida H. ER stress and diseases. FEBS Journal 274 (2007) 630-658